Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
Journal of Korean Medical Science
; : 76-83, 2014.
Article
em En
| WPRIM
| ID: wpr-200223
Biblioteca responsável:
WPRO
ABSTRACT
Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. This study investigated the efficacy of CERA for correcting anemia in Korean patients on dialysis. Patients (> or =18 yr) who were not receiving any ESAs for more than 8 weeks were randomly assigned to either intravenous CERA once every 2 weeks (n=39) or epoetin beta thrice-weekly (n=41) during a 24-week correction phase. Hemoglobin (Hb) response was defined as increase of Hb by at least 1 g/dL and Hb> or =11 g/dL without red blood cell (RBC) transfusion. Median dialysis duration was 1.7 (0.3-20.8) and 1.6 (0.4-13.8) yr in CERA and epoetin beta group, respectively. Hemoglobin response rate of CERA was 79.5% (95% confidence interval [CI], 63.5-90.7). As the lower limit of 95% CI was higher than pre-specified 60% response rate, it can be concluded that CERA corrected anemia (P<0.05). Hb response rate of epoetin beta was 87.8% (95% CI, 73.8-95.9) (P=0.37). Median time to response was 12 weeks in CERA and 10.3 weeks in epoetin beta (P=0.03). It is suggested that once every 2 weeks administration of CERA is effective for correcting anemia in Korean patients on long-term hemodialysis with longer time-to-response than thrice weekly epoetin beta. (ClinicalTrials.gov registry No. NCT00546481)
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Polietilenoglicóis
/
Qualidade de Vida
/
Proteínas Recombinantes
/
Hemoglobinas
/
Eritropoetina
/
Diálise Renal
/
Insuficiência Renal Crônica
/
República da Coreia
/
Anemia
Limite:
Female
/
Humans
/
Male
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article